Chronic administration of iminodipropionitrile (IDPN) to rats causes a persistent behavioral syndrome consisting of lateral and vertical twitches, random circling, hyperactivity, and increased startle response. These abnormalities are almost identical to those seen after acute injection of serotonin agonists and hallucinogenic drugs. The results of our quantitative autoradiographic localization studies comparing the distribution of 125I-lysergic acid diethylamide (LSD)-labeled 5-HT-2 serotonin receptors in slide-mounted sections of IDPN- and saline-treated revealed a number of changes in 5-HT-2 receptors in the brain of IDPN-treated animals. There were significant increases in the density of 5-HT-2 receptors in the frontal cortex, the cingulate cortex, and the claustrum in IDPN-treated rats. In contrast, there were significant decreases in the density of 125I-LSD binding sites in the nucleus accumbens and in the ventral region of the striatum. The present data provide further evidence to support the notion that the serotonergic system is involved in the manifestation of the persistent abnormalities induced by IDPN.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0006-8993(87)91657-xDOI Listing

Publication Analysis

Top Keywords

5-ht-2 serotonin
8
serotonin receptors
8
iminodipropionitrile idpn
8
5-ht-2 receptors
8
differential changes
4
changes 125i-lsd-labeled
4
5-ht-2
4
125i-lsd-labeled 5-ht-2
4
receptors
4
receptors discrete
4

Similar Publications

The psychoplastogens ibogaminalog and ibogainalog induce antidepressant-like activity in naïve and depressed mice by mechanisms involving 5-HT receptor activation and serotonergic transmission.

Prog Neuropsychopharmacol Biol Psychiatry

January 2025

Department of Medical Biochemistry, Rouen University Hospital, CHU de Rouen, France; Différenciation et Communication Neuroendocrine, Endocrine et Germinale Laboratory, Institute for ResearchDr.nd Innovation in Biomedicine of Normandy (IRIB), University of Rouen, INSERM 1239, 76000 Rouen, France. Electronic address:

The antidepressant-like activity of two psychoplastogens, ibogainalog (IBG) and ibogaminalog (DM506), was studied in naïve mice using the forced swim test (FST) and tail suspension test (TST). The behavioral results showed that a single administration of 25 mg/kg DM506 or 10 mg/kg IBG induced antidepressant-like activity in naïve mice in a volinanserin-sensitive manner that persisted for 72 h. Similar results were observed using the chronic immobilization stress (CIS) test, in which depression symptoms were reduced for 48 h.

View Article and Find Full Text PDF

Background: Perturbations of intestinal serotonergic neurotransmission seem to be involved in bowel dysmotility associated with irritable bowel syndrome (IBS) with diarrhea. Oral administration of probiotics is an emerging strategy to improve IBS symptoms, possibly via influencing local serotonin metabolism and neurotransmission. In the present study, we evaluated the effects of the yeast Saccharomyces boulardii CNCM I-745 (S.

View Article and Find Full Text PDF

Mirtazapine, an alpha-2 adrenergic receptor, 5-hydroxytryptamine (5-HT)2, and 5-HT3 antagonist, is commonly used in patients for depression and anorexia. Its mechanism disinhibits serotonin and norepinephrine. Though typically a well-tolerated medication, a rare adverse effect is arrhythmia, including ventricular bigeminy.

View Article and Find Full Text PDF

Neuroinflammation that is caused by microglia, the main immune cells of the brain, contributes to neurodegenerative diseases. Psychedelics, including psilocybin and lysergic acid diethylamide (LSD), possess certain anti-inflammatory properties and, therefore, should be considered as drug candidates for treating neuroinflammatory pathologies. When ingested, psilocybin is rapidly dephosphorylated to yield psilocin, which crosses the blood-brain barrier and exerts psychotropic activity by interacting with the 5-hydroxytryptamine 2A receptors (5-HTRs) on neurons.

View Article and Find Full Text PDF

Results from clinical trials show that serotonergic psychedelics have efficacy in treating psychiatric disorders, where currently approved pharmacotherapies are inadequate. Developing psychedelic medicines, however, comes with unique challenges, such as tempering heightened anxiety associated with the psychedelic experience. We conceived a new strategy to potentially mitigate psychedelic effects with defined electromagnetic signals (ES).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!